REPORT: Pharma steps up M&A, but specialty companies dominate
This article was originally published in Scrip
Executive Summary
Biopharmaceutical mergers and acquisitions more than doubled from $75bn in 2013 to $220bn in 2014 and big pharma played a larger role with $90bn in transactions last year aimed at boosting dwindling sales growth, but specialty pharmaceutical companies outspent their larger counterparts with $130bn in M&A deals with the goal of building portfolios that can compete on a global scale.